Doctors study cutting back antipsychotics: hope for fewer side effects?
NCT ID NCT07343193
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 30 adults with psychotic disorders who are stable on long-term antipsychotics and want to reduce or stop their medication. Researchers will describe real-life cases to understand what works, what doesn't, and the risks of relapse. The goal is to learn practical lessons for safer deprescribing.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide practical guidance on safely reducing or stopping antipsychotics for some stable patients, improving quality of life.
- What could go wrong
- This is a small, observational case study (30 participants) with no control group, so results may not apply broadly. Relapse risk remains a concern.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults patients with a psychotic or related disorder
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults (≥18 years) * Patients with a psychotic or related disorder * Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025 Exclusion Criteria: \- Patients who have expressed their opposition to participating in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psychotic disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Service de Psychiatrie 1 - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultrasound maps gluteal muscle to improve depot injection safety
- Gut bugs linked to antipsychotic weight gain in youth
- Hidden health crisis: new screening aims to catch physical illness in mental health patients
- Psychiatric care cuts drug harm in vietnam study
- Mirror, mirror: new study probes Self-Recognition in psychosis risk
- Heart risk in kids on psychiatric meds: new study aims for safer monitoring